+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C Drugs Market Global Forecast by Drugs, Distribution Channels, Regions, Company Analysis

  • ID: 5024111
  • Report
  • May 2020
  • Region: Global
  • 194 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbvie
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • MORE

Hepatitis C is a viral infection that causes severe damage to the human body; it is an infection caused by a virus that damages the liver, which leads to inflammation. It spread through contaminated blood. The prevalence of hepatitis C infection among the global populace is escalating. This is mainly caused by sharing needles, unsterilized medical equipment, and a blood transfusion from infected mothers to newborn babies. As per the research analysis, the Global Hepatitis C Drugs Market would be US$ 5.9 Billion by 2025.

In recent years, several drugs have been launched due to the high prevalence of Hepatitis C across the globe. The newly launched drug by AbbiVie i.e., Mavyret, has led to a downfall in the revenue of one of the market leader i.e. Gilead's. Mavyret has several advantages compared to other drugs such as its treatment course is shorter, and it is much cheaper. Harvoni drugs are popular in India, and it's easier affordable among the public.

Oral injections and dosages are required weekly in Hepatitis C; at the same time, its side effects can lead to permanent damage to other organs of patients. Around the globe, many clinical trials, as well as numerous successful drug clearances, give traction to this market. Apart from that, the rising number of regulatory approvals will further boost the market during the forecast time frame.

Hepatitis C drugs have witnessed numerous drug approvals likewise, in the year 2019, USFDA approves Mavyret for the treatment of pediatric hepatitis patients. For the treatment of all genotypes of Hepatitis C, Mavyret was the first treatment.

In the North American region, the rising adoption of hepatitis C drugs will favor the surging of the market. The market share of Asia - Pacific's and Latin American regions will grow during the forecast period.

The report titled “Hepatitis C Drugs Market Global Forecast by Drugs (Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Abbvie, Gilead Sciences, Merck, Bristol-Myers Squibb, Others)” provides a complete analysis Hepatitis C market globally.

Mavyret is the leading drug in the global hepatitis C market

Complete analysis of 7 drugs Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others are given in the report. Mavyret is the leading drug in the global hepatitis C market.

Distribution Channel is dominated by Hospital Pharmacies in the Global Hepatitis C Drugs Market.

Distribution channels like Hospital Pharmacies, Retail Pharmacies & Online Pharmacy are covered in this research report. Hospital Pharmacies is the leading distribution channel in the global hepatitis C drug market.

North America and Europe are the top two leading regions in the Global Hepatitis C Drugs Market

The report studies the hepatitis C drug market of the following regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are the top two leading regions in the global hepatitis C drug market.

All the companies have been studied from two points

  • Recent Developments
  • Sales Analysis

By Company - Global Hepatitis C Drugs Market

  • Abbvie
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb
  • Others

By Regions - Global Hepatitis C Drugs Market

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

By Drugs - Global Hepatitis C Drugs Market

  • Mavyret
  • Viekira Pak
  • Harvoni
  • Epclusa
  • Sovaldi
  • Vosevi
  • Zepatier
  • Others

By Distribution Channels - Global Hepatitis C Drugs Market

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacy
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbvie
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • MORE
1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamic
4.1 Growth Driver
4.2 Challenges

5. Global Hepatitis C Drugs Market

6. Market Share Analysis - Global Hepatitis C Drugs
6.1 Regions
6.2 Drugs
6.3 Distribution Channels
6.4 Company

7. Regions - Global Hepatitis C Drugs Market
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 Latin America
7.5 Middle East & Africa

8. Drugs - Global Hepatitis C Drugs Market
8.1 Mavyret
8.2 Viekira Pak
8.3 Harvoni
8.4 Epclusa
8.5 Sovaldi
8.6 Vosevi
8.7 Zepatier
8.8 Others

9. Distribution Channels - Global Hepatitis C Drugs Market
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacy

10. Merger and Acquisitions

11. Company Analysis - Global Hepatitis C Drugs Market
11.1 Abbvie
11.1.1 Recent Development or Strategy
11.1.2 Revenue
11.2 Gilead Sciences, Inc.
11.2.1 Recent Development or Strategy
11.2.2 Revenue
11.3 Merck & Co. Inc.
11.3.1 Recent Development or Strategy
11.3.2 Revenue
11.4 Bristol-Myers Squibb
11.4.1 Recent Development or Strategy
11.4.2 Revenue
11.5 Others

List of Figures:
Figure-01: Global Hepatitis C Drug Market, (Billion US$), 2016 - 2019
Figure-02: Global Hepatitis C Drug Market Forecast, (Billion US$), 2020 - 2025
Figure-03: Global - Hepatitis C Drugs Market Share Analysis by Regions (Percent), 2016 - 2019
Figure-04: Global - Forecast for Hepatitis C Drugs Market Share Analysis by Regions (Percent), 2020 - 2025
Figure-05: Global - Hepatitis C Drugs Market Share Analysis by Distribution Channels(Percent), 2016 - 2019
Figure-06: Global - Forecast for Hepatitis C Drugs Market Share Analysis by Distribution Channels (Percent), 2020 - 2025
Figure-07: North America - Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-08: North America - Forecast for Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-09: Europe - Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-10: Europe - Forecast for Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-11: Asia Pacific- Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-12: Asia Pacific- Forecast Hepatitis C Drug Market, (Million US$), 2020- 2025
Figure-13: Latin America - Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-14: Latin America - Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-15: Middle East & Africa - Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-16: Middle East & Africa - Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-17: Mavyret - Hepatitis C Drug Market, (Million US$), 2017 - 2019
Figure-18: Mavyret - Forecast for Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-19: Viekira Pak - Hepatitis C Drug Market, (Million US$), 2016 2019
Figure-20: Viekira Pak - Forecast for Hepatitis C Drug Market, (Million US$), 2020 -2025
Figure-21: Harvoni-Hepatitis C Drug Market, (Million US$), 2016- 2019
Figure-22: Harvoni - Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-23: Epclusa - Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-24: Epclusa- Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-25: Sovaldi- Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-26: Sovaldi- Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-27: Vosevi- Hepatitis C Drug Market, (Million US$), 2017- 2019
Figure-28: Vosevi- Forecast Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-29: Zepatier-Hepatitis C Drug Market, (Million US$), 2016 - 2019
Figure-30: Zepatier - Forecast for Hepatitis C Drug Market, (Million US$), 2020 - 2025
Figure-31: By Distribution Channels - Hospital Pharmacies Market (Million US$), 2016 - 2019
Figure-32: By Distribution Channels - Forecast For Hospital Pharmacies Market (Million US$), 2020 - 2025
Figure-33: By Distribution Channels - Retail Pharmacies Market (Million US$), 2016 - 2019
Figure-34: By Distribution Channels - Forecast For Retail Pharmacies Market (Million US$), 2020 - 2025
Figure-35: By Distribution Channels - Online Pharmacy Market (Million US$), 2016 - 2019
Figure-36: By Distribution Channels - Forecast For Retail Pharmacies Market (Million US$), 2020 - 2025
Figure-37: Global - Abbvie Company Revenue Market (Million US$), 2016 - 2019
Figure-38: Global - Abbvie Company Forecasted Revenue (Million US$), 2020 - 2025
Figure-39: Global - Gilead Sciences, Inc Revenue (Million US$), 2016 - 2019
Figure-40: Global - Gilead Sciences, Inc Forecasted Revenue (Million US$), 2020 - 2025
Figure-41: Global - Merck & Co. Inc. Company Revenue (Million US$), 2016 - 2019
Figure-42: Global - Merck & Co. Inc. Company Forecasted Revenue (Million US$), 2020 - 2025
Figure-43: Global - Bristol-Myers Squibb Company Revenue (Million US$), 2016 - 2018
Figure-44: Other Company - Revenue (Million US$), 2016 - 2019
Figure-45: Other Company - Forecasted Revenue (Million US$), 2020 - 2025

List of Tables:
Table-01: Global - Hepatitis C Drugs Market Share Analysis by Drugs (Percent), 2016 - 2019
Table-02: Global - Forecast For Hepatitis C Drugs Market Share Analysis by Drugs (Percent), 2020 - 2025
Table-03: Global - Hepatitis C Drugs Market Share Analysis by Company (Percent), 2016 - 2019
Table-04: Global - Forecast for Hepatitis C Drugs Market Share Analysis by Company (Percent), 2020 - 2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbvie
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll